



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	353234	NA NMN IMMUNITY 175,000
ARTG entry for	Medicine Listed (Export Only)	
Sponsor	Australian United Pharmaceuticals Pty Ltd	
Postal Address	Unit 6 / 17A Birmingham Avenue, Villawood, NSW, 2163 Australia	
ARTG Start Date	18/01/2021	
Product Category	Medicine	
Status	Active	
Approval Area	Export only Medicines	

Conditions

Except where the sponsor has been contracted by an overseas party to manufacturer the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods, and upon the request of the Head, Office of Prescription Medicines Authorisation Branch, Therapeutic Goods Administration, shall produce such evidence to this officer.

The sponsor shall hold stability data to support the claimed shelf life of the listed medicine according to the labelled storage conditions except where: (i) each overseas importer accepts responsibility for holding stability data for this product; (ii) the sponsor has a written agreement to this effect from each overseas importer; and (iii) the sponsor retains copies of all such agreements while the medicine remains listed on the ARTG.

This product must not be supplied for sale in Australia, including supply via duty free outlets.

Products

1 . NA NMN IMMUNITY 175,000

Product Type	Single Medicine Product	Effective Date	18/01/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Nicotinamide mononucleotide is a precursor of nicotinamide adenine dinucleotide (NAD) which is an essential cofactor in carbohydrate and fat metabolism. Maintain/support immune system health. Maintain/support energy production.

Warnings

No Warnings included on Record

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 .

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	A white oval shaped film coated tablet

Active Ingredients

nicotinamide mononucleotide	175 mg
-----------------------------	--------

Public Summary



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

Carnauba Wax

colloidal anhydrous silica

crospovidone

hypromellose

macrogol 400

magnesium stearate

microcrystalline cellulose

povidone

titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary